Improving surgery for pancreatic neuroendocrine tumors using fluorescent agents
Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10909275
This study is testing a new dye that helps surgeons see pancreatic tumors better during surgery, making it easier to remove them completely and improve recovery for patients with pancreatic neuroendocrine tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10909275 on ClinicalTrials.gov |
What this research studies
This research aims to enhance surgical outcomes for patients with pancreatic neuroendocrine tumors (pNETs) by developing a fluorescently labeled contrast agent that helps surgeons accurately identify tumors during surgery. The approach involves using a specially designed dye that targets specific receptors on the tumors, allowing for better visualization and removal. By translating a clinical radiotracer into a fluorescent agent, the study seeks to improve the effectiveness of fluorescence-guided surgery, which is crucial for achieving complete tumor removal and improving patient survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic neuroendocrine tumors who are scheduled for surgical intervention.
Not a fit: Patients with other types of pancreatic cancer or those who are not surgical candidates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective surgeries for pancreatic neuroendocrine tumors, potentially increasing survival rates and reducing the risk of cancer recurrence.
How similar studies have performed: Previous research has shown promise in using fluorescence-guided surgery with targeted agents in other cancers, indicating potential for success in this novel application.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AZHDARINIA, ALI — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: AZHDARINIA, ALI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer Center, cancer metastasis, cancer therapy, Cancer Treatment